SEC EDGAR · Insider purchase
STLN: Chernett Jorey reported buying shares
1 reported purchase of non-derivative securities. Code P includes open-market and private purchases; it does not establish motive.
Follow STLN- Became public
- Jul 13, 2026, 11:34 AM EDT
- Event / period date
- Jul 10, 2026
- Collected
- Nov 9, 2026, 7:16 PM EST
Why this is connected
This filing identifies Starling Oncology, Inc. as the issuer of the security. The company's SEC identifier connects it to STLN.
Reported transactions
Chernett Jorey (10% owner)
15,000 shares · Common Stock
Jul 10, 2026 · $5.85 per share
Value calculated from the reported shares and prices: $87,750.00.
Code P covers open-market and private purchases. Grants, option exercises, and tax withholding are excluded from purchase results. Read the source footnotes for ownership and pricing details.
Source evidence
Read the source excerpt or record
<?xml version="1.0"?>
<ownershipDocument>
<schemaVersion>X0609</schemaVersion>
<documentType>4</documentType>
<periodOfReport>2026-07-10</periodOfReport>
<notSubjectToSection16>0</notSubjectToSection16>
<issuer>
<issuerCik>0001799191</issuerCik>
<issuerName>Oncology Institute, Inc.</issuerName>
<issuerTradingSymbol>TOI</issuerTradingSymbol>
<issuerForeignTradingSymbol></issuerForeignTradingSymbol>
</issuer>
<reportingOwner>
<reportingOwnerId>
<rptOwnerCik>0002042077</rptOwnerCik>
<rptOwnerName>Chernett Jorey</rptOwnerName>
</reportingOwnerId>
<reportingOwnerAddress>
<rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
<rptOwnerStreet1>6222 INDIANWOOD TR.</rptOwnerStreet1>
<rptOwnerStreet2></rptOwnerStreet2>
<rptOwnerCity>BLOOMFIELD HILLS</rptOwnerCity>
<rptOwnerState>MI</rptOwnerState>
<rptOwnerZipCode>48301</rptOwnerZipCode>
<rptOwnerStateDescription></rptOwnerStateDescription>
</reportingOwnerAddress>
<reportingOwnerRelationship>
<isDirector>0</isDirector>
<isOfficer>0</isOfficer>
<isTenPercentOwner>1</isTenPercentOwner>
<isOther>0</isOther>
<officerTitle></officerTitle>
<otherText></otherText>
</reportingOwnerRelationship>
</reportingOwner>
<aff10b5One>0</aff10b5One>
<nonDerivativeTable>
<nonDerivativeTransaction>
<securityTitle>
<value>Common Stock</value>
</securityTitle>
<transactionDate>
<value>2026-07-10</value>
</transactionDate>
<deemedExecutionDate></deemedExecutionDate>
<transactionCoding>
<transactionFormType>4</transactionFormType>
<transactionCode>P</transactionCode>
<equitySwapInvolved>0</equitySwapInvolved>
</transactionCoding>
<transactionTimeliness></transactionTimeliness>
<transactionAmounts>
<transactionShares>
<value>15000</value>
</transactionShares>
<transactionPricePerShare>
<value>5.85</value>
<footnoteId id="F1"/>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value>A</value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value>10630858</value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
</nonDerivativeTable>
<footnotes>
<footnote id="F1">The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $5.82 to $5.90, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.</footnote>
</footnotes>
<ownerSignature>
<signatureName>/s/ Jorey Chernett</signatureName>
<signatureDate>2026-07-13</signatureDate>
</ownerSignature>
</ownershipDocument>
Price change after we could observe it
-10.71% STLN
Adjusted closing prices from Nov 11, 2026 to Nov 12, 2026. SPY changed -0.35% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in STLN
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 26, 2026$1K–$15K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$1K–$15K · Traded Sep 23, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$1K–$15K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$1K–$15K · Traded Sep 23, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$15K–$50K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$15K–$50K · Traded Sep 22, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$1K–$15K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$1K–$15K · Traded Sep 22, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$15K–$50K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$15K–$50K · Traded Sep 22, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$15K–$50K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$15K–$50K · Traded Sep 22, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$1K–$15K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$1K–$15K · Traded Sep 22, 2026 · disclosed Oct 26, 2026 · Spouse
- Oct 26, 2026$15K–$50K
Sen. Richard Blumenthal (D-CT)
Sold (partial) Starling Oncology STLN
$15K–$50K · Traded Sep 18, 2026 · disclosed Oct 26, 2026 · Spouse
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.